Fertility :: Surgery can restore male fertility

German researchers found using a minimally invasive technique to correct blocked vessels in the testicles i.e. varicoceles, one of the commonest causes of male infertility can increase the chances of fathering a child. The findings were presented at the annual meeting of the Radiological Society of North America.

Disinfectant :: Solvay’s Perestane effective against Clostridium difficile and MRSA

Perestane?, an innovative biocidal product created and developed by Solvay, has been proven to be an effective disinfectant against Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile. These so-called ?superbugs? may cause fatal diseases, and the treatment of patients with most current antibiotics is ineffective. Researchers from the University of Leeds and Leeds General Infirmary (United Kingdom) have recently demonstrated that disinfectants commonly used in hospitals fail to eradicate Clostridium difficile from the premises, and may even promote spore formation.

Health Care :: Many patients don’t understand prescription medicine labels

Many people don’t fully understand the seemingly simple label instructions on their prescription medication, according to a Northwestern University study of low-income patients. Nearly half of the patients in the study misinterpreted at least one or more out of the five prescription labels they were shown. Patients with low literacy made the most mistakes, but even people with a high-school education and higher had problems. The reason is awkward wording, according to the researcher.

Ecstasy :: Small amounts of ecstasy harmful

Even small amounts of the drug ecstasy can harm the brains of first time users, a new study shows. This is the first study to examine the effects of low doses of ecstasy on the brain. The study was presented at the annual meeting of the Radiological Society of North America, in Chicago.

Embolism :: Oral anticoagulant rivaroxaban shows efficacy and safety for prevention of VTE

Phase II clinical trial results published today in Circulation (2006;114:2374-2381) highlight the potential of a simple, once-daily dosing regimen of the novel, oral anticoagulant rivaroxaban (BAY 59-7939), a direct Factor Xa inhibitor. In this trial, rivaroxaban demonstrated that it may have similar safety and efficacy to subcutaneous enoxaparin (the current standard), for the prevention of venous thromboembolism (VTE) in patients undergoing elective total hip replacement surgery.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack